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Abstract: Development of a novel delivery system has been attempted to deliver viable probiotic 
cells into the gut for a prolonged period of time while maintaining high numbers of viable cells 
within the formulation throughout the shelf-life of the product and during the gastrointestinal 
transit. Core mucoadhesive microspheres of Bacillus coagulans were developed employing 
several grades of hypromellose, a mucoadhesive polymer, following coacervation and phase 
separation technique and were subsequently enteric-coated with hypromellose phthalate. 
Microspheres were evaluated for percent yield; entrapment efficiency; in vitro swelling; surface 
morphology; particle size, size distribution, and zeta potential; flow property, mucoadhesion 
property by the ex vivo mucoadhesive strength test and the in vitro wash off test; in vitro release 
profile and release kinetic; in vivo probiotic activity; and stability. The values for the kinetic 
constant and regression coefficient of model-dependent approaches and the difference factor ( f1), 
the similarity factor ( f2), and the Rescigno index (ξ1 and ξ2) of model independent approaches 
were determined for comparing in vitro dissolution profiles. Freeze dried B. coagulans cells 
were successfully formulated as enteric-coated mucoadhesive microspheres with satisfactory 
physical structure and yield. The viability of B. coagulans was maintained in the simulated gastric 
conditions and during processing; in simulated intestinal conditions exhibiting mucoadhesion, 
and controlling and extending the viable cell release following zero-order; and was satisfactorily 
stable at room temperature. Test results depict statistically significant effects of the hypromellose 
grade and their concentration on the performance and release profile of formulations.
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Introduction
Reported health benefits of probiotics such as suppressing the growth of undesirable 
microorganisms in the colon and in the small intestine, controlling serum cholesterol 
level, reducing the risk of colon cancer, stimulating the immune system, improving 
lactose utilization, and controlling the allergic inflammation associated with food allergy 
has created a large market of probiotic foods worldwide.1–7 The therapeutic benefit of 
probiotics is associated with its ability to secrete a bacteriocin, coagulin, which is active 
against a broad spectrum of enteric microbes.7 To be therapeutically active, probiotics 
must arrive in the intestine alive and in sufficient numbers which is suggested at 106–107 
colony-forming units (cfu).8 B. coagulans, commonly mislabeled as Lactobacillus 
sporogenes, also suffers with wide variation between the actual content and the labeled 
claim of viable spores, as in other probiotic strains.7,9 Reduction in cell viability within 
the dosage form results from the freeze-drying operation of probiotics during the initial 
manufacturing, the processing conditions during formulation, and noncompliance to International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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storage requirements during transportation and storage.7–12 
After their consumption, the hydrolytic enzymes, the acidic 
conditions of stomach, and the bile salts in the gastrointestinal 
(GI) tract also adversely affect the viability of probiotics.7,12–15 
Various approaches such as the addition of different growth 
promoters, manipulation of fermentation and storage 
conditions of the food carriers, careful selection of the culture 
organisms according to their interrelationships and acid-bile 
resistance, and employing microencapsulation technology 
have been investigated to improve the amount of viable 
cells arriving in the intestine.7,13–15 However, all of these 
approaches have varying degrees of success, as maintenance 
of high numbers of viable cells within the product throughout 
its shelf-life and during GI transit is a challenge. Amongst 
all the above approaches, microencapsulation technologies 
have attracted considerable attention but their short residence 
time at the site of action/absorption limits their performance. 
Coupling mucoadhesion characteristics to microspheres 
through developing mucoadhesive microspheres in turn 
will enhance their residence time and specifically can target 
drug(s) to the site of action/absorption and thereby enhance 
performance.16,17 Hypromellose has been used as a polymer 
in the preparation of mucoadhesive microspheres due to its 
favorable mucoadhesive properties, and is safe for human 
oral consumption.16–18 Hypromellose and hypromellose 
phthalate are compatible with B. coagulans19 and possess 
aqueous solubility.20
In the context of the above principles, there is a need to 
develop a dosage form that will deliver B. coagulans into 
the gut for a prolonged period of time with adequate stability 
during storage and GI transit. Thus, the present investigation 
attempted to prepare B. coagulans loaded mucoadhesive 
microspheres, using several grades of hypromellose and 
subsequently enteric-coated with hypromellose phthalate, 
in order to deliver viable B. coagulans into the gut for an 
extended period of time protecting against the harsh condi-
tions of the GI tract and having an adequate shelf-life.
Materials and methods
Materials
Freeze dried B. coagulans (powder) and hypromellose 
phthalate (HP-50) were gift samples from Glenmark 
Pharmaceuticals Limited (Sinnar, Nasik, India). Grades of 
hypromellose (hydroxypropylmethylcellulose or HPMC) 
namely Methocel E5 Premium LV , Methocel E15 Premium 
LV, and Methocel K15M Premium were received from 
Indoco Remedies Limited (Rabale, Mumbai, India). Glucose 
Yeast Extract (GYE), agar media, and other analytical 
grade laboratory chemicals were purchased from HiMedia 
Laboratories Pvt Limited (Mumbai, India).
Methods
In-house compliance test of B. coagulans
Identification tests (description, microscopic examination, 
qualitative test for lactic acid production), viable B.   coagulans 
spore count, estimation of the lactic acid-producing capacity, 
determination of loss on drying, and ensuring the absence 
of contaminants were done as per the method of analysis 
provided by the manufacturer.
Preparation of mucoadhesive microspheres
Core B. coagulans loaded mucoadhesive microspheres 
were prepared with hypromellose, employing coacervation 
and phase separation technique.16,17 Briefly, hypromellose 
(2.5 g) was dissolved in 100 mL of cold de-ionized 
(DI) water (4 ± 2°C). One hundred mg of tween-80 was 
dissolved in the above solution with stirring. Resultant 
solution was filtered aseptically using 0.45 µm PVDF filter 
membrane (Millipore, Bedford, MA). A calculated quantity 
of B. coagulans was dispersed in the above solution, under 
stirring. The temperature of the resultant dispersion was 
raised gradually up to 30 ± 2°C with stirring at 500 ± 25 
revolutions per minute (rpm) for 30 minutes. Acetone 
(25 mL) was added drop-wise with stirring at 300 ± 25 rpm 
for 10 minutes. Microspheres thus obtained were filtered 
aseptically with 10 µm nylon filter (NY10; Millipore), 
washed twice with sterile water for injection (30 ± 2°C) and 
then kept in a desiccator for 24 hours. The entire process was 
carried out aseptically on a bench of horizontal laminar flow 
clean air work station (1500048-24-24; Klenzaids Bioclean 
Devices (P) Ltd, Mumbai, India). All formulation batches 
were prepared in triplicate following the above method to 
verify reproducibility and their composition is summarized 
in Table 1.
coating of microspheres
One hundred mL of hypromellose phthalate solution (10% 
w/w) was prepared by dissolving HP-50 in phosphate buffer 
pH-6.821 with stirring. Two g of polyethylene glycol 200 
(PEG-200) and 100 mg of tween-80 was added to it with 
stirring. The above solution was filtered aseptically using 
a 0.45 µm PVDF filter membrane. Core microspheres were 
dispersed in the above solution with stirring at 300 ± 25 rpm 
followed by drop-wise addition of 20 mL of propan-2-ol. 
Stirring was continued for 30 minutes. Coated microspheres, 
thus obtained, were filtered and washed thrice with sterile International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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water for injection (30 ± 2°C), kept in a desiccator for 
24 hours, transferred aseptically to a sterile glass vial, 
sealed hermetically, and stored in a refrigerator for further 
manipulation. The entire process was carried out aseptically 
on a bench of horizontal laminar flow clean air work station, 
in triplicate to observe reproducibility of the process.
Percent yield study
Percent yield (w/w) of microspheres was calculated 
employing equation-1.
Percenty ield
W1(Weightof microsphererecovered)
W2 (Weight[dru
=
g g+polymer])
× 100 (1)
calibration curve of B. coagulans
Several standard concentrations of dispersions   containing 
B. coagulans were prepared with the sterile simulated 
gastric fluid TS and the sterile simulated intestinal fluid TS 
separately. The respective absorbance optical density (OD) 
was measured at 600 nm with respect to their respective 
blank, employing UV/Vis spectroscopic method (UV-1700; 
Shimadzu, Kyoto, Japan), so as to get a calibration curve 
that relates the OD values to cell concentration.22 When a 
standard B. coagulans dispersion was analyzed repeatedly 
(n = 3), the mean error (accuracy) was found to be 0.98% 
and relative standard deviation (precision) was found to 
be 1.5%, indicating validity of the method for linearity, 
accuracy, and precision. The OD test is the best way to 
enumerate roughly the total number of cells (viable plus 
nonviable) present in the sample and helps to determine the 
dilution factor for performing viable spore count but fails to 
reveal cfu, the unit for expressing the number of viable cells. 
The simulated gastric fluid TS21 and the simulated intestinal 
fluid TS21   contains inorganic salts but no carbon source, 
thus B. coagulans cells will not proliferate in this media but 
will remain in a state of stasis until they are plated on media 
containing a carbon source.
Viable B. coagulans spore count
The number of viable spores in the sample was determined 
by employing the following procedure.19
Dilution and heat-treatment
One gram of sample alternating with 1 mL of sample solu-
tion containing B. coagulans was transferred aseptically into 
a pre-sterilized 10 mL volumetric flask containing 5 mL of 
sterile saline TS and mixed thoroughly by sonication for 
2   minutes. The volume was made up to 10 mL with sterile 
saline TS. One mL of the above suspension was diluted to 
10 mL with sterile saline TS in an autoclaved test tube (25 mm 
by 150 mm size). This serial dilution method was contin-
ued until a suitable dilution was achieved (approximately 
100 cell/mL). The final dilution tube was allowed to stand in 
a water bath at 70°C for 30 minutes and then cooled immedi-
ately to about 45°C. Saline TS21 contains inorganic salts but 
no carbon source; thus B. coagulans will not proliferate in 
this media but will remain in a state of stasis until they are 
plated on media containing carbon source.
Plating
GYE agar medium was liquefied and cooled to 45°C in a 
water bath. One mL of sample from the heat-treated final 
dilution tube was transferred into each sterile petri dish (six 
per sample) followed by pouring 15 mL of molten medium 
and mixing and then incubating in an inverted position at 
40°C for 48 hours after solidification.
counting
Six plates were counted and the average count per plate 
was calculated. The number of cfu per unit (mL or gram) of 
sample was calculated by employing equation-2.
Table 1 Formulation formula and percent yield value and entrapment efficiency value of all formulation batches
Formulation  
code
Polymer used B. coagulans to  
polymer ratio
Percent yield  
(w/w)*
Entrapment efficiency   
(% w/w)*
F1 Methocel e5  
Premium LV
1:1 68.1 ± 3.12  85.36 ± 2.23
F2 1:2 66.6 ± 3.09 78.41 ± 1.76
F3 1:3 64.4 ± 3.18 72.22 ± 1.76
F4 Methocel e15  
Premium LV
1:1 65.3 ± 3.59 78.00 ± 2.31
F5 1:2 63.4 ± 3.67 74.92 ± 1.91
F6 1:3 62.1 ± 3.24  70.68 ± 1.79
F7 Methocel K15M  
Premium
1:1 59.4 ± 3.17  73.56 ± 2.54
F8 1:2 56.2 ± 3.81 71.74 ± 2.86
F9 1:3 54.6 ± 3.46 67.68 ± 2.31
Note: *Data are presented as mean value ± se, n = 3.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Numberof cfu
Averagenumberofc oloniescountedperplate
Dilution
=
f factor
  (2)
Entrapment efficiency study
Two hundred mg of accurately weighed microspheres were 
transferred aseptically into a sterile glass vial containing 
10 mL of sterile simulated intestinal fluid TS, sealed 
  hermetically and kept at 4 ± 2°C for 24 hours. The dispersion 
was subjected to a viable B. coagulans spore count and the 
entrapment efficiency value was calculated using equation-3 
and is reported in percent.
Entrapment efficiency
Practical spore count
Theoretical spo
=
r re count
00 × 1   (3)
In vitro swelling study
An in vitro swelling test of microspheres was conducted in 
simulated intestinal fluid TS. The size of dried microspheres 
and those after incubation in simulated intestinal fluid for 
5 hours were measured using a calibrated optical microscope 
(CX RIII; Labomed, Ambala, India). Percent swelling value 
was determined from the diameter of microspheres at time t 
(DT) and initial time t = 0 (D0) using equation-4.23
  Percent swelling = [DT − D0]/D0 × 100  (4)
Morphological examination of microspheres
Coated microspheres were mounted on the aluminum stubs 
using double-sided adhesive tape. The stubs were then vacuum-
coated with a thin layer of gold and examined with a scanning 
electron microscope (JSM 5610 LV; Jeol, Tokyo, Japan).16
Particle size, size distribution, and zeta potential 
study
The core and the coated microspheres were dispersed in DI 
water (pH 6.8) and sonicated for 2 minutes to get a homogenous 
dispersion (0.5% w/v). The resultant dispersions contained in 
small volume disposable zeta cells were subjected to particle 
size study using photon correlation spectroscopy with in-built 
Zetasizer (Nano ZS; Malvern Instruments, Worcestershire, UK) 
at 633 nm and 25 ± 0.1°C. Measured electrophoretic mobility 
(mm/s) is converted to zeta potential by in-built software based 
on the Helmholtz–Smoluchowski equation.24
Flow property study
The flow property of coated microspheres was determined 
from the results of study parameters namely: Angle of repose 
(α), equation-5; Carr’s index (CI), equation-6; and Hausner 
ratio (HR), equation-7.21 Angle of repose was determined 
by the fixed funnel method and is calculated from the height 
(H) and the radius (R) of the powder hip. Microspheres were 
placed in a graduated cylinder and the initial volume before 
tapping (V0) was noted then they were tapped with a tap 
density apparatus (ETD-1020; Electrolab, Mumbai, India) 
to a constant volume so as to get tapped volume (VT).
	α  = tan−1 [H/R]  (5)
  CI = [(V0 – VT)/V0] × 100  (6)
  HR = V0/VT  (7)
Mucoadhesion test
The mucoadhesion properties of coated microspheres were 
studied to examine the adhesiveness of the microspheres to 
the mucosa at the site of absorption/application, following 
institutional animal ethical committee guidelines and were 
performed by the following tests:
ex vivo mucoadhesive strength determination
The coated microsphere suspension was prepared in 
simulated intestinal fluid TS, and the number of microsphere 
per mL (No) was determined by optical microscopy. One mL 
of the above suspension was fed to overnight-fasted Albino 
rats of either sex (in a group of four) using an oral feeding 
needle. The rats were sacrificed at an interval of 0, 4, 8, and 
12 hours to isolate their stomach and intestinal region. The 
stomach and intestines were then cut open longitudinally to 
count the number of microspheres adhering to these regions 
(NS). Percent adhesive strength test result of all formulation 
batches was reported in percent adhesive strength and was 
calculated using equation-8.17
  Percent adhesive strength = [NS/N0] × 100  (8)
In vitro wash-off test
Freshly excised pieces of intestinal mucosa (2 cm × 2 cm) 
from sheep were mounted onto a glass slide (8 cm × 3 cm) 
with cyanoacrylate glue. Coated microspheres (100 numbers) 
were accurately counted and were spread onto wet rinsed 
intestinal mucosa tissue followed by hanging it onto one 
of the groves of a USP tablet disintegration test apparatus 
(DT 1000; Labindia Instruments Pvt Ltd, Mumbai, India), 
with continuous oxygen supply. The apparatus was operated 
giving tissue specimen regular up-and-down movements 
within the beaker of disintegration test apparatus, containing International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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simulated intestinal fluid TS at 37 ± 1°C.25 The number of 
microspheres still adhering onto the tissue was counted at 
hourly intervals up to 12 hours.
In vitro release study
The in vitro release profile of B. coagulans from coated 
microspheres was studied using a USP basket apparatus 
(TDT-06T; Electrolab, Mumbai, India) at 37 ± 0.5°C and 
100 rpm containing 900 mL of sterile dissolution medium, 
namely, the simulated gastric fluid TS and the simulated 
intestinal fluid TS. About 500 mg of accurately weighed 
coated microspheres was placed in a basket (wrapped with 
100 mesh nylon cloth) of the dissolution apparatus. Five mL 
of dissolution medium was withdrawn at a predetermined 
time interval up to 18 hours followed by immediate 
replacement with an equal volume of fresh dissolution 
medium. After suitable dilution samples were subjected for 
viable spore count, the result was presented as percent viable 
B. coagulans cells released.
In vitro release kinetic studies, statistical evaluation, 
and data fitting
The kinetic model describes drug dissolution from the solid 
dosage form, where the dissolved amount of the drug as a 
function of test time was studied. Under appropriate test 
conditions, a dissolution profile can characterize the product 
more precisely than a single point dissolution test. A mean 
value of three determinations at each time point was used 
to fit an in vitro drug dissolution profile of all formulation 
batches to different kinetic models so as to find the best 
fitting kinetic model and to determine their release exponents, 
while the mean value of twelve determinations was used to 
estimate the factors of the model-independent approach.26,27 
In vitro release kinetic studies, statistical evaluation, data 
fitting, nonlinear least square curve fitting, simulation, and 
plotting were performed using Excel software (v 2007; 
Microsoft Software Inc, Redmond, WA) so as to determine 
the parameters of each equation.
ANOVA-based procedures
Statistical analysis of in vitro release data and other data were 
performed using one way ANOVA at a significance level of 
5% (P , 0.05) using Excel.
Model-independent methods (pair-wise procedures)
A comparison of the dissolution profile between products 
helps to assure similarity in product performance and shows 
bioequivalence. The model-independent mathematical 
approach is employed to compare the dissolution profile 
using three factors: f1, equation-9; f2, equation-10; and 
Rescigno index (ξi), equation-11. According to the nature 
of measurement, f1 was described as the difference fac-
tor and f2 as the similarity factor and are determined by 
employing cumulative data. The factor f1 is proportional 
to the average difference between the two profiles and 
indicates the percent error between two curves over all 
time points, whereas factor f2 is inversely proportional to 
the average squared difference between two profiles and is 
a logarithmic transformation of the sum-squared error of 
difference between the test Tt and reference products Rt. 
Rescigno index (ξ1 and ξ2), a dimensional index, refer to 
area differences for noncumulative data and refer to the 
difference between the dissolved amount of the test and 
reference product in a given time interval.
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Note that Rt is the cumulative percentage dissolved from 
the reference product; Tt is from the test product at each of 
the selected time points, n, of the test and the product; dT (t) 
is the test product dissolved amount; dR (t) is the reference 
product dissolved amount at each time point; and i is any 
positive integer number.
Model-dependent methods
Model-dependent mathematical approaches including 
zero order, first order, Hixson–Crowell and Weibull 
model, as listed in Table 2, were applied considering the 
amount of viable cell release as a function of test time. 
The following plots were then plotted: cumulative percent 
viable cell release vs time (zero order kinetic model), log 
cumulative percent viable cell release vs time (first order 
kinetic model), cube root of percent drug remaining in 
matrix vs time (Hixson–Crowell cube root), and logarithm 
of the dissolved amount of drug vs the logarithm of time 
(Weibull model). Higuchi model was not considered as the 
prepared microspheres fail to comply to the assumptions 
of this model.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In vivo probiotic activity evaluation
An in vivo probiotic activity evaluation of coated microspheres 
was performed using the mouse model Enterococci stool 
colonization method described by Donskey et al following 
institutional animal ethical committee guidelines. One mL 
of coated microspheres dispersion (102 cfu/mL), in simulated 
intestinal fluid TS, was orally fed to mice (in a group of 
six) using an oral feeding needle. The stools were collected 
periodically at six hour intervals up to 48 hours and subjected 
for enterococci colonization density study.9
Accelerated stability study of microspheres
Following ICH guidelines, formulation batches of micro-
spheres were stored at several conditions of temperature 
and humidity (30 ± 2°C/65 ± 5% RH and 40 ± 2°C/75 ± 5% 
RH) in a stability analysis chamber (Darwin Chambers 
Company, St Louis, MO) and in a refrigerator (2–8°C) for 
a period of 12 weeks.28 The samples were subjected for 
viable B. coagulans cell content, color, and texture analysis 
at 2-week intervals. These results were compared with those 
of the initial results (results of analysis of samples prior to 
stability charging) and control samples kept at 2–8°C. The 
absence of any statistically significant decrease in viable 
B. coagulans cell content indicates product stability with the 
excipient and at the storage condition.
Results and discussion
The coacervation and phase separation technique described 
here appears to be a suitable method for the preparation 
of enteric-coated hypromellose microspheres loaded with 
B. coagulans. It is a two-step process, simple and less time 
consuming, and eliminates the exposure of B. coagulans 
to high temperatures, organic solvents, and mechanical 
stress, thereby maintaining their viability during processing. 
Temperatures above 20°C and nonaqueous solvents adversely 
affect and decrease the viability of B. coagulans, thus the 
developmental processes of enteric-coated microsphere was 
carried out below 20°C in aqueous medium. Hypromellose is 
soluble in cold water and its solubility in water decreases with 
increase in temperature and is insoluble in organic solvents 
such as chloroform, dichloromethane, ether, and acetone.20 
Hypromellose phthalate is soluble in aqueous alkali and 
is insoluble in water and propan-2-ol.20 Hypromellose as 
a mucoadhesive polymer and hypromellose phthalate as a 
coating polymer were selected due to their abovementioned 
properties. Tween-80 was incorporated in the formulation as 
a dispersing agent for homogenously dispersing B. coagulans 
cells and PEG-200 was incorporated in the coating solution 
formulation as a plasticizer to impart plasticity to the coat 
and to prevent it from splitting and cracking.
The percent yield value of the formulation batches lie 
within the range 54.6%–68.1% w/w while entrapment 
efficiency value lies within the range 67.68%–85.36% w/w, 
and both were found to vary with differences in the grade 
of hypromellose and the B. coagulans-to-hypromellose ratio 
(Table 1). The highest percent yield value was observed with 
the formulation containing Methocel E5 Premium LV . The 
effect of the grade of hypromellose on percent yield value is 
the following order: Methocel E5 Premium LV . Methocel 
E15 Premium LV . Methocel K15M Premium. A similar 
trend was also found in the case of the entrapment 
efficiency value and the highest value was also observed 
with formulations containing Methocel E5 Premium LV. 
It was also observed that the percent yield and entrapment 
efficiency values increase with a decrease in B. coagulans-
to-hypromellose ratio (Table 1).
The percent swelling value varies with differences in the 
grade of HPMC, and the maximum percent swelling value 
was observed with Methocel E5 Premium LV. The effect 
of the grade of hypromellose on the percent swelling value 
follows the order of Methocel E5 Premium LV . Methocel 
E15 Premium LV . Methocel K15M Premium while the 
B. coagulans-to-HPMC ratio does not have a statistically 
significant effect on the percent swelling value. The percent 
swelling value of all formulation batches lies between 0.85 
and 1.36 (Table 3).
Prepared B. coagulans loaded mucoadhesive microspheres 
were spherical in shape with a smooth surface and had no 
holes/ruptures on the surface. A scanning electron microscopy 
photograph of formulation-F1 which enumerates microsphere 
particle size and morphology is shown in Figure 1.
The mean particle size value of all formulation batches 
lies between 26.61 µm and 49.01 µm (Table 3). Variation 
in the mean particle size was observed with differences in 
Table 2 Mathematical models used to describe dissolution curves
Zero order Q1 = Q0 + K0t
First order ln W1 = ln W0 + Kt
hixson–crowell Q0
1/3-Q1
1/3 = Kst
Weibull log[-ln(1-m)] = b log (t-Ti) − log α
Notes: Where Q0 is the initial amount of drug in the pharmaceutical dosage form, 
Q1 is the amount of drug in the pharmaceutical dosage form at time t, W0 is initial 
amount of drug in the dosage form, W1 is the amount of drug released in time t, 
and K0 is the zero order proportionality constant, and K is the first order release 
rate constant, Ks is a constant incorporating the surface-volume relation, m  is 
the accumulated fraction of the drug in solution at time t, α is the time scale of 
the process, Ti is the location parameter represents the lag time before the onset 
of the dissolution or release process, and b is the shape parameter.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the grade of hypromellose. The highest mean particle size 
value was observed with formulations containing Methocel 
K15M Premium. The effect of the grade of hypromellose on 
the mean particle size value follows the order of Methocel 
K15M Premium . Methocel E15 Premium LV . Methocel 
E5 Premium LV (Figure 2 and Table 3). Variation in 
B. coagulans-to-hypromellose ratio does not influence the 
mean particle size value of formulation batches. The zeta 
potential value (Table 3) of core microspheres was negative 
as expected due to the methoxy group of hypromellose. Core 
microspheres prepared with the Methocel E15 Premium LV 
and the Methocel E5 Premium LV possessed nearly the same 
zeta potential value as both have the same ratio of methoxy 
and hydroxypropoxy groups, and are both higher than that 
prepared with Methocel K15M Premium. This may be due to 
an increase in the methoxy content of hypromellose polymer. 
A nearly constant negative zeta potential value (−7.66 ± 0.87) 
was observed with coated microspheres of all formulation 
batches, which is lower than that of uncoated microspheres, 
confirms the presence of hypromellose phthalate on the 
surface of microspheres. The zeta potential report of uncoated 
microspheres from formulation-F1 is presented in Figure 3. 
The flow properties of formulation batches lie between the 
passable and very poor range.
The percent adhesive strength value of all formulation 
batches, as a measure of ex vivo mucoadhesive strength 
test, lies between 72.3% and 83.1%, and an increase in 
B.   coagulans-to-hypromellose ratio does not affect it 
(Table 3). The highest percent adhesive strength value was 
observed with Methocel E5 Premium LV and the effect of 
the grade of hypromellose on percent adhesive strength value 
follows the order of Methocel E5 Premium LV . Methocel 
E15 Premium LV . Methocel K15M Premium. The in vitro 
wash-off test results (Table 4), as a measure of mucoadhesive 
efficiency, reveals that even after 12 hours, some of the 
microspheres remained adhered to the intestinal mucosa 
indicating that microspheres possess strong mucoadhesion 
affinity for the intestinal mucosa. The above experimental 
results suggest that mucoadhesion properties of microspheres 
vary with differences in the grade of polymer and does not 
vary with differences in the B. coagulans-to-hypromellose 
ratio. Microspheres possessing strong mucoadhesion affinity 
Table 3 Percent swelling, mean particle size, zeta potential, and percent adhesive strength values of microspheres of all formulation 
batches
Formulation code Percent swelling Mean particle  
size (μm)
Zeta potential (mV) of  
uncoated microspheres
Percent adhesive 
strength
F1 1.23 ± 0.61 26.614 ± 1.15 −15.86 ± 0.45 83.1 ± 1.23
F2 1.28 ± 0.56 27.036 ± 1.34 −15.61 ± 0.92 83.4 ± 1.35
F3 1.36 ± 0.59 27.134 ± 1.64 −16.01 ± 0.81 82.8 ± 1.37
F4 1.10 ± 0.50 33.453 ± 1.58 −16.17 ± 0.65 78.1 ± 1.17
F5 1.14 ± 0.54 34.248 ± 1.71 −16.06 ± 0.83 78.9 ± 1.24
F6 1.19 ± 0.59 33.264 ± 1.39 −15.97 ± 0.67 78.5 ± 1.41
F7 0.85 ± 0.34 48.409 ± 2.32 −13.67 ± 0.87 72.6 ± 1.36
F8 0.87 ± 0.46 48.952 ± 2.24 −13.45 ± 0.53 73.8 ± 1.16
F9 0.89 ± 0.41 49.013 ± 2.19 −13.28 ± 0.41 72.3 ± 1.14
Note: Data are presented as mean value ± se, n = 3.
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for intestinal mucosa may thus be retained in the intestinal 
tract for an extended period of time.
In simulated gastric fluid TS, the amount of B. coagulans 
released from the coated microsphere system is negligible, 
while in simulated intestinal fluid TS, B. coagulans release 
is almost regulated and extended within the investigational 
period of 18 hours (Figure 4). This indicates that enteric-
coating of microspheres has been competently protecting the 
viability of B. coagulans in gastric pH, preventing the release 
of B. coagulans in gastric pH, and releasing B. coagulans 
in the intestinal pH.
The model independent (pair wise approach) release 
exponents (f1, f2, ξ1 and ξ2) values are listed in Table 5. 
Normally, regulatory authorities have set a public standard 
of f1 values between 1 and 15, and f2 values between 50 and 
100 to indicate similarity between two dissolution profiles, 
while the ξ1 and ξ2 indices always present values between 
0 and 1 inclusive, where an index value of 0 denotes two 
identical release profiles, and a value of 1 denotes when the 
drug from either the test or the reference is not released at 
all.26,27 Data from Table 5 reveal that, for all formulation pairs, 
the ξ1 values lie between 0.06 and 0.24, and ξ2 values lies 
between 0.14 and 0.32 (ie, above 0 and below 1), and the f1 
value lies between 16.85 and 42.60 (ie, above 15), and for 
almost all formulation pairs, the f2 value lies between 27.54 
and 50.00 (ie, below 50) indicating dissimilarity in product 
performance of the formulation batches when compared 
to each other, ie, intrapolymer (having the same grade of 
hypromellose but differing from each other by B. coagulans-
to-hypromellose ratio) and interpolymer (having the same 
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Figure 3 Zeta potential report of uncoated microspheres from formulation batch F1.
Table 4 results of in vitro wash-off test of all formulation batches
Formulation  
code
Percent microspheres adhering to tissue at time points (in hours)
1 h 2 h 4 h 6 h 8 h 10 h 12 h
F1 62 ± 1.6 49 ± 2.0 34 ± 2.1 22 ± 1.9 16 ± 1.5 13 ± 1.2 09 ± 1.1
F2 63 ± 1.2 45 ± 1.0 36 ± 1.4 24 ± 1.8 18 ± 1.7 12 ± 1.1 08 ± 0.8
F3 69 ± 2.2 48 ± 1.1 32 ± 1.8 21 ± 1.6 15 ± 1.3 10 ± 1.5 07 ± 1.1
F4 71 ± 2.1 58 ± 1.2 41 ± 1.6 33 ± 1.7 22 ± 2.0 15 ± 1.9 09 ± 1.0
F5 72 ± 1.9 57 ± 2.3 39 ± 2.0 32 ± 1.5 24 ± 1.8 16 ± 1.8 11 ± 1.8
F6 73 ± 2.0 60 ± 1.8 43 ± 2.2 35 ± 1.9 26 ± 2.0 18 ± 1.9 12 ± 1.7
F7 89 ± 2.1 79 ± 2.1 62 ± 2.0 40 ± 1.5 32 ± 2.1 26 ± 2.0 16 ± 1.9
F8 86 ± 1.8 76 ± 2.4 61 ± 2.1 39 ± 1.9 29 ± 1.9 18 ± 2.2 13 ± 1.5
F9 85 ± 1.5 74 ± 2.0 58 ± 2.3 43 ± 2.1 30 ± 1.9 21 ± 1.7 12 ± 2.0
Note: Data are presented as mean value ± se, n = 3.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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ratio of B. coagulans-to-hypromellose but differs from each 
other by grade of hypromellose).
The values for the kinetic constant and release exponent 
of model-dependent approaches (zero-order, Weibull) are 
listed in Table 6. The mechanism of B. coagulans release 
from the microspheres follows the zero-order kinetic model, 
since the plot of cumulative percent viable cell release versus 
time were found to be linear, and have a highest regression 
coefficient (r2) value in comparison to that of the first order, 
Hixson–Crowell, and Weibull model when compared with 
intraformulation batches. For all formulation batches, the 
zero-order kinetic model r2 value lies between 0.9820 and 
0.9978, while the zero-order kinetic constant value lies 
between 2.3708 and 5.5517. In Weibull model, the shape 
parameter characterizes the curve as either exponential 
(β = 1, case-1), sigmoid or S-shaped with upward curvature 
followed by a turning point (β . 1, case-2), or parabolic 
with a higher initial slope, and after that consistent with the 
exponential (β , 1, case-3), while the location parameter 
(Td) characterizes the time interval necessary to dissolve 
or release 63.2% of the drug present in the pharmaceutical 
dosage form, determined by employing relation α = (Td)β 
from the shape parameter (β) and scale parameter (α).27 
Study of shape parameter values of the Weibull model 
from Table 6 reveal that the curve is sigmoid or S-shaped 
with upward curvature followed by a turning point (β . 1), 
while the Td value of all formulation batches lies between 
9.31 and 30.06.
A plot showing the viable B. coagulans release profile 
following the zero-order kinetic model of all formulation 
batches is shown in Figure 4, and reveals that an increase in 
the B. coagulans-to-polymer ratio significantly decreases the 
rate of viable B. coagulans release from microspheres while 
variation in the grade of hypromellose influences the rate of 
viable B. coagulans release from microspheres following 
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Figure 4 Comparative dissolution profile (model dependent, Zero-order kinetic model) of all formulation batches.
Table 5 Mean value of dissimilarity factor (f1), similarity factor 
(f2), and two indices of rescigno (ξ1 and ξ2)
Formulation pair f1 f2 ξ1 ξ2
F1 vs F2 24.000 40.000 0.1212 0.1691
F1 vs F3 42.397 27.543 0.2128 0.3154
F2 vs F3 24.000 45.000 0.0941 0.2264
F4 vs F5 21.279 47.073 0.1091 0.1422
F4 vs F6 42.604 31.385 0.2401 0.3033
F5 vs F6 27.089 45.404 0.1345 0.2362
F7 vs F8 16.854 56.251 0.0752 0.2012
F7 vs F9 38.000 39.000 0.2147 0.3027
F8 vs F9 25.924 51.836 0.1418 0.1818
F1 vs F4 21.316 41.613 0.0729 0.2126
F1 vs F7 40.594 28.665 0.2091 0.2742
F4 vs F7 24.500 44.421 0.1383 0.2290
F2 vs F5 19.419 47.993 0.0607 0.2614
F2 vs F8 34.406 36.711 0.1643 0.2751
F5 vs F8 19.476 53.487 0.1046 0.1861
F3 vs F6 24.409 49.132 0.1014 0.2626
F3 vs F9 35.860 41.129 0.2110 0.2733
F6 vs F9 18.000 63.000 0.1120 0.2117International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the order of Methocel E5 Premium LV . Methocel E15 
Premium LV . Methocel K15M Premium.
In vivo probiotic activity evaluation showed that oral 
administration of coated microspheres of B. coagulans from 
all formulation batches resulted in statistically significant 
reductions in the density of enterococci colonization in the 
stool of Albino mice from 24 hours to 36 hours. Satisfactory 
in vivo probiotic activity in the mouse model showed that the 
prepared B. coagulans loaded microspheres have potential for 
follow-up studies to verify its potentiality for human use.
The stability results reveal that prepared B. coagulans 
loaded microspheres exhibit adequate stability at the stor-
age condition of 30 ± 2°C/65 ± 5% RH, as no statistically 
significant decreases in viable B. coagulans cell content were 
observed, and also signifies that the B. coagulans cells are 
compatible with the excipients used in the development of 
microspheres. At the storage condition of 40 ± 2°C/75 ± 5% 
RH, statistically significant decrease in viable B. coagulans 
cell content was observed, indicating product instability at 
this storage condition.
Formulation F1 (containing B. coagulans-to-Methocel E5 
Premium LV with ratio of 1:1) was found to be superior to 
the other prototype formulations with respect to product per-
formance, as it exhibited the highest entrapment efficiency, 
highest mucoadhesion efficiency, the ability to protect the 
viability of B. coagulans cells during storage and GI tran-
sit, and releases viable B. coagulans cells in the gut for an 
extended period of time, as shown via zero-order kinetics.
Conclusion
Experimental results suggest that enteric-coated hypromel-
lose microspheres loaded with B. coagulans could be 
prepared by the conventional coacervation and phase 
separation method, and have the potential to deliver viable 
B. coagulans cells into the gut for an extended period of 
time, while maintaining the viability of B. coagulans during 
storage and GI transit, and could be viewed as an alternative 
to conventional dosage forms. However, extensive in vivo 
studies are required to establish the use of mucoadhesive 
microspheres as an alternative to conventional dosage forms 
of B. coagulans.
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